Recent studies into retatritide peptide demonstrate significant outlook for managing excess body and non-insulin dependent diabetes. The compound, a dual stimulator of GLP-1 receptor and GIP, seems to present greater weight reduction and blood sugar control in contrast to existing medications. Further research efforts are required to fully evaluate